Interventions
Per the initial dosing regimen, BGB-A333 and tislelizumab were administered IV on Day 1 of each 21-day cycle (Q3W). For study arms involving BGB-A333 monotherapy, the infusion of BGB-A333 was administered over 60 (±5) min. If the drug was well tolerated in the first three cycles, on Cycle 4 Day 1 and subsequent cycles, BGB-A333 could be administered over 30 (±5) min.For study arms requiring combination treatment, in Cycles 1 and 2, tislelizumab was administered over 60 (±5) min followed by the administration of BGB-A333 over 60 (±5) min. If infusions were well tolerated in the first two cycles, on Cycle 3 Day 1, tislelizumab could be administered over 30 (±5) min followed by the administration of BGB-A333 over 60 (±5) min. If infusions of tislelizumab and BGB-A333 were well tolerated in the first three cycles, on Cycle 4 Day 1 and subsequent cycles, tislelizumab could be administered over 30 (±5) min followed by the administration of BGB-A333 over 30 (±5) min.Dose reduction was not permitted for either BGB-A333 or tislelizumab; criteria for dose delay or modification are described in the 